Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in adolescents with plasma therapy-sensitive atypical hemolytic uremic syndrome
NL-OMON33085Phase 2Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of eculizumab in atypical hemolytic uremic syndrome (aHUS) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: TMA-event free status. Started Nov 2009; status: active, not recruiting.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NL-OMON33085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33085.